Table 1. Main pretreatment characteristics.
|
CMF
|
CMF → GT
|
A → CMF
|
A → CMF → GT
|
|||||
|---|---|---|---|---|---|---|---|---|
| No. of patients | 114 | 120 | 119 | 113 | ||||
| Tumour size | ||||||||
| Median (cm) | 2 | 2.2 | 2.5 | 2.5 | ||||
| Range (cm) | 0.5–10 | 1–8 | 0.18–20 | 0.7–9.5 | ||||
| Age (years) | ||||||||
| Median | 45 | 44 | 43 | 44 | ||||
| Range | 29–52 | 28–51 | 20–51 | 25–50 | ||||
| ER receptor | ||||||||
| Positive | 49 | 43% | 41 | 34% | 37 | 31% | 48 | 42% |
| Negative | 30 | 26% | 27 | 23% | 24 | 20% | 15 | 13% |
| Unknown | 35 | 31% | 52 | 43% | 58 | 49% | 50 | 44% |
| PgR receptor | ||||||||
| Positive | 41 | 36% | 37 | 31% | 35 | 29% | 41 | 36% |
| Negative | 33 | 29% | 24 | 20% | 20 | 17% | 19 | 17% |
| Unknown | 40 | 35% | 59 | 49% | 64 | 54% | 53 | 47% |
| Node metastases | ||||||||
| 1–3 | 64 | 56% | 64 | 53% | 64 | 54% | 61 | 54% |
| 4+ | 50 | 44% | 56 | 46% | 55 | 46% | 52 | 46% |
| Grading | ||||||||
| 1 | 3 | 3% | 3 | 3% | 4 | 3% | 1 | 1% |
| 2 | 27 | 24% | 24 | 20% | 30 | 25% | 23 | 20% |
| 3 | 44 | 39% | 50 | 42% | 43 | 36% | 50 | 44% |
| Unknown | 40 | 35% | 43 | 36% | 42 | 35% | 39 | 35% |
CMF=CMF × 6 cycles; CMF → GT=CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years; A → CMF=doxorubicin × 4 cycles followed by CMF × 6 cycles; A → CMF → GT=doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years; ER receptor=oestrogen receptor; PgR receptor=progesterone receptor; CMF=cyclophosphamide, methotrexate, fluorouracil.